Logo

OMCL

Omnicell, Inc.

OMCL

Omnicell, Inc. • NASDAQ
$36.51 ▼ -0.41% (-0.15)
Market Cap $1.69 B
52w High $47.84
52w Low $22.66
Dividend Yield 0%
P/E 84.91
Volume 87.92K
Outstanding Shares 46.31M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $310.631M ▲ $126.259M ▲ $5.462M ▼ 1.758% ▼ $0.12 $30.564M ▲
Q2-2025 $290.562M ▲ $119.558M ▼ $5.639M ▲ 1.941% ▲ $0.12 ▲ $30.04M ▲
Q1-2025 $269.668M ▼ $122.555M ▼ $-7.023M ▼ -2.604% ▼ $-0.15 ▼ $10.222M ▼
Q4-2024 $306.879M ▲ $129.161M ▲ $15.842M ▲ 5.162% ▲ $0.34 ▲ $46.922M ▲
Q3-2024 $282.42M $115.726M $8.63M 3.056% $0.19 $34.321M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $180.053M ▼ $1.949B ▼ $727.695M ▼ $1.221B ▼
Q2-2025 $411.633M ▲ $2.145B ▼ $881.877M ▼ $1.264B ▲
Q1-2025 $399.427M ▲ $2.151B ▲ $894.37M ▲ $1.257B ▲
Q4-2024 $381.676M ▼ $2.121B ▼ $877.647M ▼ $1.243B ▲
Q3-2024 $582.327M $2.304B $1.072B $1.231B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $5.462M ▼ $28.267M ▼ $-14.281M ▲ $-219.981M ▼ $-206.045M ▼ $18.514M ▼
Q2-2025 $5.639M ▲ $42.755M ▲ $-15.923M ▼ $-11.469M ▼ $17.098M ▲ $30.974M ▲
Q1-2025 $-7.023M ▼ $25.924M ▼ $-15.739M ▼ $4.038M ▲ $15.788M ▲ $14.752M ▼
Q4-2024 $15.842M ▲ $56.315M ▲ $-13.568M ▼ $-234.43M ▼ $-194.314M ▼ $47.228M ▲
Q3-2024 $8.63M $22.754M $-13.336M $3.554M $14.611M $9.418M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Connected Devices Software Licenses And Other
Connected Devices Software Licenses And Other
 $160.00M ▲$120.00M ▼$140.00M ▲$150.00M ▲
Consumables
Consumables
 $20.00M ▲$30.00M ▲$20.00M ▼$20.00M ▲
Hardware And Software
Hardware And Software
 $0 ▲$60.00M ▲$60.00M ▲$70.00M ▲
Technical Services
Technical Services
 $60.00M ▲$60.00M ▲$60.00M ▲$70.00M ▲
Advanced Services
Advanced Services
 $60.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown meaningfully over the past five years but has cooled off since its peak, showing that the company moved from a strong growth spurt into more of a digestion phase. Profitability has been choppy: Omnicell slipped into a small loss during the middle of the period and has only recently returned to slightly positive earnings. Gross profit remains healthy, but operating and net margins are thin, which means the business does not have much cushion if growth slows or costs rise. Overall, this looks like a company with a solid revenue base but still working to stabilize and rebuild its profitability after a bumpy couple of years.

Balance Sheet

Balance Sheet The balance sheet shows a business with a sizable asset base built up over time, supported by growing shareholder equity. Cash levels are comfortable rather than excessive, giving some flexibility but not a huge war chest. Debt increased in earlier years and has started to edge down, suggesting management is paying attention to leverage but still carries a meaningful level of borrowing. In simple terms, the company looks reasonably well-capitalized, with a balance between debt and equity that is manageable but worth monitoring if profitability remains thin.

Cash Flow

Cash Flow Cash generation is a relative bright spot. Omnicell has consistently produced positive operating cash flow and, after investments, positive free cash flow as well. Cash flow dipped when earnings were under more pressure but has recovered, pointing to decent underlying business quality and working capital management. Capital spending has been steady and not overly aggressive, indicating disciplined investment rather than a cash-hungry model. Overall, cash flows look more stable than accounting earnings, which provides some comfort around the company’s ability to fund its own operations and ongoing investments.

Competitive Edge

Competitive Edge Omnicell holds a strong position in the niche of pharmacy automation and medication management, especially in hospitals and large health systems. Its systems are deeply embedded in customer workflows, which makes switching providers costly, disruptive, and unlikely without a strong reason. The company benefits from a large installed base and long-term relationships with major health systems and retail pharmacies, providing recurring revenue and cross‑sell opportunities. Competition is real—particularly from a major rival in Pyxis—but Omnicell’s end‑to‑end platform, integration of hardware, software, and services, and brand recognition create a meaningful competitive moat.

Innovation and R&D

Innovation and R&D Innovation is at the core of Omnicell’s strategy. The “Autonomous Pharmacy” vision ties together robotics, automated dispensing, cloud software, and data analytics into a unified platform. New offerings like Omnicell One, OmniSphere, and RFID-based MedTrack solutions show a deliberate push toward smarter, data-driven medication management. The Austin Innovation Lab highlights ongoing commitment to R&D, especially in AI and predictive analytics. The company is also pivoting toward technology-enabled services and specialty pharmacy support, which could increase recurring, higher-value revenue but also introduces execution risk as it shifts its business model.

Summary

Omnicell is an established healthcare technology player with a strong niche in medication automation and a clear innovation agenda. Financially, it has moved from a growth and margin expansion phase into a more mixed period, with softer revenue, thin profitability, but steady and positive cash generation. The balance sheet is sound enough to support ongoing investment, though not completely insulated from prolonged earnings pressure. Strategically, the company’s embedded systems, large customer base, and integrated platform provide a solid competitive foundation, while its push into AI, cloud platforms, and services offers long-term opportunity. The main watchpoints are the company’s ability to restore healthier margins, sustain demand in a budget‑constrained hospital environment, and execute smoothly on its transition toward more service- and software-driven revenue.

NEWS

November 20, 2025 · 4:01 PM UTC

Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference

Read more

November 13, 2025 · 8:00 AM UTC

Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies

Read more

October 30, 2025 · 6:30 AM UTC

Omnicell Announces Third Quarter 2025 Financial Results

Read more

October 6, 2025 · 4:01 PM UTC

Omnicell to Release Third Quarter 2025 Financial Results on October 30, 2025

Read more